Intralesional Triamcinolone Acetonide and Its Combination With 5-fluorouracil in Keloids and Hypertrophic Scars

NACompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

January 28, 2021

Primary Completion Date

August 14, 2021

Study Completion Date

September 14, 2021

Conditions
Scar Keloid
Interventions
DRUG

5-Fluorouracil

Group A: 1ml of 40mg/ml triamcinolone acetonide will be mixed with 1ml of normal saline Group B:1 ml of 40 mg/ml triamcinolone acetonide will be mixed with 1ml of 50 mg/ml FU Five units (0.125ml) of the mixture TAC 40mg/ml and 5-FU 50mg/ml (1:1) i.e. 2.5mg TAC and 3.125mg of 5-FU or TAC 40mg/ml and 2%xylocaine (1:1) i.e. 2.5mg of TAC will be given intralesional with the help of 1ml insulin syringe of 40units, that covers an area of about 0.5X0.5 cm2 of scar, thus, a scar of 1 cm2 will require 4 injections to cover the whole lesion. Each extra area of 0.5x0.5cm2 will be given 5 units of injection of above mixture of drugs. For the larger lesions, dose can be increased but no more than 2ml in each group. Injection will be given at 2 weeks interval for total of 6 sessions (at 0,2, 4, 6,8,10 weeks) Post treatment follow up: at 12 weeks.

Trial Locations (1)

025

B.P. Koirala Institute of Health Sciences, Dharān

All Listed Sponsors
collaborator

Nepal Health Research Council

OTHER_GOV

lead

B.P. Koirala Institute of Health Sciences

OTHER

NCT04812626 - Intralesional Triamcinolone Acetonide and Its Combination With 5-fluorouracil in Keloids and Hypertrophic Scars | Biotech Hunter | Biotech Hunter